Topical calcitriol protects from UV-induced genetic damage but suppresses cutaneous immunity in humans.
Calcitriol, the biologically active form of vitamin D, has been reported to cause both suppressive and protective immune effects in mice. Its immune effects in vivo in humans are unclear. We investigated the in vivo effects of topical calcitriol on minimal erythema dose and skin immune responses in healthy volunteers. We found that calcitriol did not protect from ultraviolet (UV)-induced erythema (sunburn) when applied either 24 h before or immediately after irradiation, although it decreased the density of sunburn cells and thymine dimers seen on biopsy when applied 24 h before and again immediately after irradiation. Using the Mantoux reaction as a model of skin immunity, we found that topical calcitriol applied at high total doses reduced the Mantoux responses of nearby untreated, unirradiated skin, suggesting a para-local or systemic immunosuppressive effect not observed with lower calcitriol doses. We then measured UV-induced suppression of Mantoux reactions at vehicle-treated sites and sites treated with low-dose calcitriol, and found that calcitriol neither reduced nor enhanced UV-induced immunosuppression. Despite calcitriol reducing UV-induced DNA damage, which should protect the immune system, it has immunosuppressive effects in our model which may help to explain the efficacy of analogues such as calcipotriol in the treatment of psoriasis.
Damian
Diona L
DL
Dermatology, Sydney Cancer Centre, Royal Prince Alfred Hospital, University of Sydney, Camperdown, NSW, Australia.
Kim
Young Jin
YJ
Dixon
Katie M
KM
Halliday
Gary M
GM
Javeri
Arash
A
Mason
Rebecca S
RS
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D001706:Biopsy; D002117:Calcitriol / Q000008:administration & dosage / Q000627:therapeutic use*; D004249:DNA Damage / Q000187:drug effects* / Q000528:radiation effects*; D004305:Dose-Response Relationship, Drug; D004890:Erythema / Q000188:drug therapy / Q000517:prevention & control; D005260:Female; D006801:Humans; D007109:Immunity / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D014677:Pharmaceutical Vehicles; D012867:Skin / Q000276:immunology* / Q000473:pathology; D016896:Treatment Outcome; D014466:Ultraviolet Rays / Q000009:adverse effects*; D014807:Vitamin D / Q000008:administration & dosage / Q000627:therapeutic use*
D014677:Pharmaceutical Vehicles; D014807:Vitamin D; D002117:Calcitriol